Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,446 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor.
Yin O, Zahir H, French J, Polhamus D, Wang X, van de Sande M, Tap WD, Gelderblom H, Wagner AJ, Healey JH, Greenberg J, Shuster D, Stacchiotti S. Yin O, et al. Among authors: french j. CPT Pharmacometrics Syst Pharmacol. 2021 Nov;10(11):1422-1432. doi: 10.1002/psp4.12712. Epub 2021 Oct 14. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34585528 Free PMC article.
Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
Chen SC, Quartino A, Polhamus D, Riggs M, French J, Wang X, Vadhavkar S, Smitt M, Hoersch S, Strasak A, Jin JY, Girish S, Li C. Chen SC, et al. Among authors: french j. Br J Clin Pharmacol. 2017 Dec;83(12):2767-2777. doi: 10.1111/bcp.13381. Epub 2017 Sep 3. Br J Clin Pharmacol. 2017. PMID: 28733983 Free PMC article. Clinical Trial.
Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
Li C, Wang B, Chen SC, Wada R, Lu D, Wang X, Polhamus D, French J, Vadhavkar S, Strasak A, Smitt M, Joshi A, Samant M, Quartino A, Jin J, Girish S. Li C, et al. Among authors: french j. Cancer Chemother Pharmacol. 2017 Dec;80(6):1079-1090. doi: 10.1007/s00280-017-3440-4. Epub 2017 Oct 11. Cancer Chemother Pharmacol. 2017. PMID: 29022084 Clinical Trial.
Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
Lu D, Li C, Riggs M, Polhamus D, French J, Agarwal P, Chen SC, Vadhavkar S, Patre M, Strasak A, Quartino A, Jin JY, Girish S. Lu D, et al. Among authors: french j. Cancer Chemother Pharmacol. 2019 Jul;84(1):175-185. doi: 10.1007/s00280-019-03852-z. Epub 2019 May 17. Cancer Chemother Pharmacol. 2019. PMID: 31102024 Clinical Trial.
Welcome to the statistics and pharmacometrics themed issue.
French J, Mentré F. French J, et al. CPT Pharmacometrics Syst Pharmacol. 2021 Apr;10(4):273-274. doi: 10.1002/psp4.12625. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 33951754 Free PMC article. No abstract available.
Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab.
Terranova N, French J, Dai H, Wiens M, Khandelwal A, Ruiz-Garcia A, Manitz J, von Heydebreck A, Ruisi M, Chin K, Girard P, Venkatakrishnan K. Terranova N, et al. Among authors: french j. CPT Pharmacometrics Syst Pharmacol. 2022 Mar;11(3):333-347. doi: 10.1002/psp4.12754. Epub 2022 Jan 19. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 34971492 Free PMC article. Clinical Trial.
Variable or variate? A conundrum in pharmacometrics exposure-response models.
Grisic AM, Venkatakrishnan K, French J, Khandelwal A. Grisic AM, et al. Among authors: french j. CPT Pharmacometrics Syst Pharmacol. 2023 Feb;12(2):144-147. doi: 10.1002/psp4.12905. Epub 2022 Dec 29. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36537836 Free PMC article.
Confounded exposure metrics.
Wiens MR, French JL, Rogers JA. Wiens MR, et al. CPT Pharmacometrics Syst Pharmacol. 2024 Feb;13(2):187-191. doi: 10.1002/psp4.13074. Epub 2023 Nov 20. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 37984457 Free PMC article. No abstract available.
Bayesian estimation in NONMEM.
Johnston CK, Waterhouse T, Wiens M, Mondick J, French J, Gillespie WR. Johnston CK, et al. Among authors: french j. CPT Pharmacometrics Syst Pharmacol. 2024 Feb;13(2):192-207. doi: 10.1002/psp4.13088. Epub 2023 Dec 8. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38017712 Free PMC article.
Model-based meta-analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus.
Goteti K, Garcia R, Gillespie WR, French J, Klopp-Schulze L, Li Y, Mateo CV, Roy S, Guenther O, Benincosa L, Venkatakrishnan K. Goteti K, et al. Among authors: french j. CPT Pharmacometrics Syst Pharmacol. 2024 Feb;13(2):281-295. doi: 10.1002/psp4.13083. Epub 2023 Dec 4. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38050332 Free PMC article.
2,446 results